MedTrace Logo

Biofeedback and Hydrogen Water as Treatments for Chronic Fatigue Syndrome

NCT05397626 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2022-05-31

No results posted yet for this study

Summary

The aim of this 10-week pilot study is to explore the potential benefit of two recently developed non-invasive interventions, heart rate variability biofeedback (HRV-BF) and OTC supplement hydrogen water, for the symptoms of chronic fatigue syndrome (CFS). Symptom measures and heart monitoring information will be generated by this study. Given the lack of effective treatments in this illness, these two non-invasive home-based treatments may help patients feel and function better.

Conditions

  • Chronic Fatigue Syndrome

Interventions

BEHAVIORAL

Heart Rhythm Biofeedback

Heart rhythm biofeedback is a non-invasive intervention intended to improve heart rate variability and physical resilience that is often limited in chronic fatigue syndrome

DIETARY_SUPPLEMENT

Hydrogen Water

Hydrogen water, if ingested daily over several weeks, may have antioxidant and anti-inflammatory effects in chronic fatigue syndrome

COMBINATION_PRODUCT

Combined treatment: Heart rhythm biofeedback plus hydrogen water

This treatment is intended to explore the possible additive or synergistic effects of combining heart rhythm biofeedback and hydrogen water.

Sponsors & Collaborators

Principal Investigators

  • FRED FRIEDBERG, Phd · Stony Brook University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-23
Primary Completion
2023-05-23
Completion
2023-05-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05397626 on ClinicalTrials.gov